Patterns of transmitted HIV drug resistance in Europe vary by risk group.
<h4>Background</h4>In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported.<h4>Methods</h4>HIV-1...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/cb11271513de4669a456b9fb91457921 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:cb11271513de4669a456b9fb91457921 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:cb11271513de4669a456b9fb914579212021-11-18T08:24:04ZPatterns of transmitted HIV drug resistance in Europe vary by risk group.1932-620310.1371/journal.pone.0094495https://doaj.org/article/cb11271513de4669a456b9fb914579212014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24721998/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported.<h4>Methods</h4>HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression.<h4>Results</h4>From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM were more often from Western Europe origin, infected with subtype B virus, and recently infected (<1 year) (p<0.001). The prevalence of TDRM was highest in MSM (prevalence of 11.1%), followed by heterosexuals (6.6%) and IDU (5.1%, p<0.001). TDRM was predominantly ascribed to nucleoside reverse transcriptase inhibitors (NRTI) with a prevalence of 6.6% in MSM, 3.3% in heterosexuals and 2.0% in IDU (p = 0.001). A significant increase in resistance to non- nucleoside reverse transcriptase inhibitors (NNRTIs) and a decrease in resistance to protease inhibitors was observed in MSM (p = 0.008 and p = 0.006, respectively), but not in heterosexual patients (p = 0.68 and p = 0.14, respectively).<h4>Conclusions</h4>MSM showed to have significantly higher TDRM prevalence compared to heterosexuals and IDU. The increasing NNRTI resistance in MSM is likely to negatively influence the therapy response of first-line therapy, as most include NNRTI drugs.Dineke FrentzDavid van de VijverAna AbecasisJan AlbertOsamah HamoudaLouise JørgensenClaudia KüchererDaniel StruckJean-Claude SchmitJurgen VercauterenBirgitta AsjöClaudia BalottaColm BerginDanail BeshkovRicardo CamachoBonaventura ClotetAlgirdas GriskeviciusZehava GrossmanAndrzej HorbanTatjana KolupajevaKlaus KornLeondios KostrikisKirsi Liitsola Marek LinkaClaus NielsenDan OteleaDimitrios ParaskevisRoger ParedesMario PoljakElisabeth Puchhammer-StöcklAnders SönnerborgDanica StanekovaMaja StanojevicAnne-Mieke VandammeCharles BoucherAnnemarie WensingSPREAD ProgrammePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 4, p e94495 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Dineke Frentz David van de Vijver Ana Abecasis Jan Albert Osamah Hamouda Louise Jørgensen Claudia Kücherer Daniel Struck Jean-Claude Schmit Jurgen Vercauteren Birgitta Asjö Claudia Balotta Colm Bergin Danail Beshkov Ricardo Camacho Bonaventura Clotet Algirdas Griskevicius Zehava Grossman Andrzej Horban Tatjana Kolupajeva Klaus Korn Leondios Kostrikis Kirsi Liitsola Marek Linka Claus Nielsen Dan Otelea Dimitrios Paraskevis Roger Paredes Mario Poljak Elisabeth Puchhammer-Stöckl Anders Sönnerborg Danica Stanekova Maja Stanojevic Anne-Mieke Vandamme Charles Boucher Annemarie Wensing SPREAD Programme Patterns of transmitted HIV drug resistance in Europe vary by risk group. |
| description |
<h4>Background</h4>In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported.<h4>Methods</h4>HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression.<h4>Results</h4>From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM were more often from Western Europe origin, infected with subtype B virus, and recently infected (<1 year) (p<0.001). The prevalence of TDRM was highest in MSM (prevalence of 11.1%), followed by heterosexuals (6.6%) and IDU (5.1%, p<0.001). TDRM was predominantly ascribed to nucleoside reverse transcriptase inhibitors (NRTI) with a prevalence of 6.6% in MSM, 3.3% in heterosexuals and 2.0% in IDU (p = 0.001). A significant increase in resistance to non- nucleoside reverse transcriptase inhibitors (NNRTIs) and a decrease in resistance to protease inhibitors was observed in MSM (p = 0.008 and p = 0.006, respectively), but not in heterosexual patients (p = 0.68 and p = 0.14, respectively).<h4>Conclusions</h4>MSM showed to have significantly higher TDRM prevalence compared to heterosexuals and IDU. The increasing NNRTI resistance in MSM is likely to negatively influence the therapy response of first-line therapy, as most include NNRTI drugs. |
| format |
article |
| author |
Dineke Frentz David van de Vijver Ana Abecasis Jan Albert Osamah Hamouda Louise Jørgensen Claudia Kücherer Daniel Struck Jean-Claude Schmit Jurgen Vercauteren Birgitta Asjö Claudia Balotta Colm Bergin Danail Beshkov Ricardo Camacho Bonaventura Clotet Algirdas Griskevicius Zehava Grossman Andrzej Horban Tatjana Kolupajeva Klaus Korn Leondios Kostrikis Kirsi Liitsola Marek Linka Claus Nielsen Dan Otelea Dimitrios Paraskevis Roger Paredes Mario Poljak Elisabeth Puchhammer-Stöckl Anders Sönnerborg Danica Stanekova Maja Stanojevic Anne-Mieke Vandamme Charles Boucher Annemarie Wensing SPREAD Programme |
| author_facet |
Dineke Frentz David van de Vijver Ana Abecasis Jan Albert Osamah Hamouda Louise Jørgensen Claudia Kücherer Daniel Struck Jean-Claude Schmit Jurgen Vercauteren Birgitta Asjö Claudia Balotta Colm Bergin Danail Beshkov Ricardo Camacho Bonaventura Clotet Algirdas Griskevicius Zehava Grossman Andrzej Horban Tatjana Kolupajeva Klaus Korn Leondios Kostrikis Kirsi Liitsola Marek Linka Claus Nielsen Dan Otelea Dimitrios Paraskevis Roger Paredes Mario Poljak Elisabeth Puchhammer-Stöckl Anders Sönnerborg Danica Stanekova Maja Stanojevic Anne-Mieke Vandamme Charles Boucher Annemarie Wensing SPREAD Programme |
| author_sort |
Dineke Frentz |
| title |
Patterns of transmitted HIV drug resistance in Europe vary by risk group. |
| title_short |
Patterns of transmitted HIV drug resistance in Europe vary by risk group. |
| title_full |
Patterns of transmitted HIV drug resistance in Europe vary by risk group. |
| title_fullStr |
Patterns of transmitted HIV drug resistance in Europe vary by risk group. |
| title_full_unstemmed |
Patterns of transmitted HIV drug resistance in Europe vary by risk group. |
| title_sort |
patterns of transmitted hiv drug resistance in europe vary by risk group. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2014 |
| url |
https://doaj.org/article/cb11271513de4669a456b9fb91457921 |
| work_keys_str_mv |
AT dinekefrentz patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT davidvandevijver patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT anaabecasis patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT janalbert patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT osamahhamouda patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT louisejørgensen patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT claudiakucherer patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT danielstruck patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT jeanclaudeschmit patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT jurgenvercauteren patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT birgittaasjo patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT claudiabalotta patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT colmbergin patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT danailbeshkov patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT ricardocamacho patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT bonaventuraclotet patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT algirdasgriskevicius patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT zehavagrossman patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT andrzejhorban patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT tatjanakolupajeva patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT klauskorn patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT leondioskostrikis patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT kirsiliitsolamareklinka patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT clausnielsen patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT danotelea patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT dimitriosparaskevis patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT rogerparedes patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT mariopoljak patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT elisabethpuchhammerstockl patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT anderssonnerborg patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT danicastanekova patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT majastanojevic patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT annemiekevandamme patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT charlesboucher patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT annemariewensing patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup AT spreadprogramme patternsoftransmittedhivdrugresistanceineuropevarybyriskgroup |
| _version_ |
1718421889953562624 |